Identifying pseudo-resistant hypertension and optimizing diuretic therapy for confirmed resistant cases in primary care.

IF 1.6 Q3 PHARMACOLOGY & PHARMACY Canadian Pharmacists Journal Pub Date : 2024-10-03 DOI:10.1177/17151635241281511
Joey Champigny, Jeff Nagge
{"title":"Identifying pseudo-resistant hypertension and optimizing diuretic therapy for confirmed resistant cases in primary care.","authors":"Joey Champigny, Jeff Nagge","doi":"10.1177/17151635241281511","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Approximately 10% of individuals with hypertension are expected to have resistant hypertension (RH). Many have pseudo-resistant hypertension (p-RH) due to a variety of factors. To date, the prevalence of p-RH and optimal diuretic therapy in primary care have not been studied.</p><p><strong>Methods: </strong>A retrospective chart review was conducted, including patients referred to the hypertension clinic at the Centre for Family Medicine (CFFM) Family Health Team in Kitchener, ON, from January 2010 to September 2020. Individuals ≥18 years old referred to clinic by their family physician or other health care provider with 2 consecutive blood pressure (BP) readings of ≥140/90 mmHg despite using ≥3 antihypertensive agents were included.</p><p><strong>Results: </strong>Fifty-one patients taking ≥3 antihypertensive agents were referred during the study timeframe. Forty-one patients had ≥2 consecutive BP readings of ≥140/90 and were classified as having presumed RH. Of these, 24 patients (59%) had p-RH after BP was measured systematically in the hypertension clinic. Of the 17 with RH, 5 (29%) were prescribed optimal diuretic therapy upon referral. Most common clinic interventions included initiating or adjusting the dose of a diuretic (47%), adding a different antihypertensive agent (27%) or discontinuing an antihypertensive agent due to side effects (24%).</p><p><strong>Discussion: </strong>To our knowledge, this is the first time that the prevalence of p-RH and optimal diuretic therapy have been studied in primary care. p-RH was common and diuretic therapy was underused in RH.</p><p><strong>Conclusion: </strong>This study suggests that p-RH is prevalent and diuretic therapy underused in primary care. Systematic BP measurement and optimization of diuretic therapy should be prioritized prior to specialist referral.</p>","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":" ","pages":"17151635241281511"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556601/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Pharmacists Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/17151635241281511","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Approximately 10% of individuals with hypertension are expected to have resistant hypertension (RH). Many have pseudo-resistant hypertension (p-RH) due to a variety of factors. To date, the prevalence of p-RH and optimal diuretic therapy in primary care have not been studied.

Methods: A retrospective chart review was conducted, including patients referred to the hypertension clinic at the Centre for Family Medicine (CFFM) Family Health Team in Kitchener, ON, from January 2010 to September 2020. Individuals ≥18 years old referred to clinic by their family physician or other health care provider with 2 consecutive blood pressure (BP) readings of ≥140/90 mmHg despite using ≥3 antihypertensive agents were included.

Results: Fifty-one patients taking ≥3 antihypertensive agents were referred during the study timeframe. Forty-one patients had ≥2 consecutive BP readings of ≥140/90 and were classified as having presumed RH. Of these, 24 patients (59%) had p-RH after BP was measured systematically in the hypertension clinic. Of the 17 with RH, 5 (29%) were prescribed optimal diuretic therapy upon referral. Most common clinic interventions included initiating or adjusting the dose of a diuretic (47%), adding a different antihypertensive agent (27%) or discontinuing an antihypertensive agent due to side effects (24%).

Discussion: To our knowledge, this is the first time that the prevalence of p-RH and optimal diuretic therapy have been studied in primary care. p-RH was common and diuretic therapy was underused in RH.

Conclusion: This study suggests that p-RH is prevalent and diuretic therapy underused in primary care. Systematic BP measurement and optimization of diuretic therapy should be prioritized prior to specialist referral.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
识别假性耐药高血压,优化初级保健中确诊耐药病例的利尿剂治疗。
背景:预计约有 10% 的高血压患者会出现抵抗性高血压 (RH)。由于各种因素,许多人患有假性抵抗性高血压(p-RH)。迄今为止,尚未研究过 p-RH 的患病率和初级医疗中的最佳利尿剂疗法:方法:我们对 2010 年 1 月至 2020 年 9 月期间转诊至安大略省基奇纳家庭医学中心(CFFM)家庭保健团队高血压门诊的患者进行了回顾性病历审查。患者年龄≥18岁,由家庭医生或其他医疗保健提供者转诊,连续两次血压(BP)读数≥140/90 mmHg,但使用了≥3种降压药物:研究期间转诊了 51 名服用≥3 种抗高血压药物的患者。41 名患者连续两次血压读数≥140/90,被归类为假定 RH。其中,24 名患者(59%)在高血压诊所系统测量血压后出现 p-RH。在 17 名 RH 患者中,有 5 人(29%)在转诊时接受了最佳利尿剂治疗。最常见的门诊干预措施包括开始使用或调整利尿剂剂量(47%)、添加不同的降压药(27%)或因副作用停用降压药(24%):据我们所知,这是首次在初级保健中研究 p-RH 的患病率和最佳利尿剂疗法:这项研究表明,p-RH 在初级保健中很普遍,而利尿剂疗法却未得到充分利用。在专科医生转诊前,应优先进行系统的血压测量和优化利尿剂治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Canadian Pharmacists Journal
Canadian Pharmacists Journal PHARMACOLOGY & PHARMACY-
CiteScore
2.50
自引率
26.70%
发文量
43
期刊介绍: Established in 1868, the Canadian Pharmacists Journal is the oldest continuously published periodical in Canada. Our mission is to enhance patient care through advancement of pharmacy practice, with continuing professional development, peer-reviewed research, and advocacy. Our vision is to become the foremost journal for pharmacy practice and research.
期刊最新文献
The role of Alberta pharmacists working in opioid use disorder and their potential to prescribe buprenorphine-naloxone: A qualitative study. Opportunities and challenges associated with the launch of nirmatrelvir/ritonavir (Paxlovid) in British Columbia during the COVID-19 pandemic: A qualitative study to explore community pharmacists' perspectives. Lyme disease chemoprophylaxis prescribing before and after pharmacist prescriptive authority in Nova Scotia. Enabling pharmacist prescribing: Lessons learned in Nova Scotia using behaviour change theory. British Columbia community pharmacy during COVID-19: Describing the patient experience via Google reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1